Academician Chen Wei: Nebulized and inhaled new crown vaccine is applying for emergency use

The 2021 Pujiang Innovation Forum hosted by the Ministry of Science and Technology and the Shanghai Municipal Government held a plenary session on June 3.

The new drug clinical application was submitted on March 9, 2020, the clinical trial was officially started on March 16, the first clinical data of the new crown vaccine was published in the world on May 22, and the vaccine was approved by the Food and Drug Administration on February 25 this year.

"The first shot of the new crown vaccine was given to Wuhan, which gave us a lot of confidence in scientific research.

In her view, strong scientific research confidence comes from years of accumulation and the country's continuous investment in science and technology.

"2018 marks the 40th anniversary of our country's implementation of the immunization plan.

At the same time, the rapid development of a new coronavirus vaccine is inseparable from the country's continuous investment in science and technology.

Regarding the impact of the virus mutation on the vaccine, which is of great concern to the public, Chen Wei said that the South African strain has a greater impact on the vaccine.

Chen Wei also mentioned that his team is studying dual non-vaccine, that is, non-injection, non-cold chain vaccine.

She explained that the nebulized inhalation vaccine only needs one-fifth of the dose of the injection vaccine, and the bottleneck problem of the vaccine bottle can be solved without the need to bottle one.

According to the data, the so-called nebulized inhalation immunity is the use of a nebulizer to atomize the vaccine into tiny particles, which enter the respiratory tract and lungs through breathing inhalation, thereby stimulating mucosal immunity, which cannot be brought by intramuscular injection.